November 2002 – The CenterWatch Monthly : Volume 9, Issue 11, November 2002
Expanding the Boundaries of CRO Partnerships
During the past several years, contract research organizations (CROs) including PPD, Quintiles and AaiPharma have expanded their abilities to perform most drug development company functions – from discovery of new molecules to selling approved drugs. Client companies are largely comfortable and eager to leverage these broadening capabilities.
Revisiting the Online Matchmaker Market
Internet-based companies that match patients to trials are tempering their promises and changing their business models in order to differentiate themselves in a skeptical market where adoption has been limited.
CentreStage Europe: A Tenuous SMO Market in Europe
European site management organizations are continuing to struggle to gain recognition as valuable assets in the clinical trial process. The SMO market in Europe remains poorly understood and ill-defined.
Eye On: HIV/AIDS
CenterWatch has identified a pipeline of 52 drugs in development for HIV/AIDS, including immune modulators, fusion inhibitors, vaccines and others.
- Month in Review
- In the Pipeline
- Opportunities Underway